Connect with us

News

Canada added over 6,000 new coronavirus cases each day since Friday, new data shows – Global News

Published

 on


Canada is now adding new coronavirus infections at a rate over three times what was seen during the first peak of the pandemic in May, new data reveals, as the country ends a particularly brutal month of rising cases and deaths.

The country saw 6,103 new cases of COVID-19 Monday, after the daily number inched closer to the 6,000-mark throughout the previous week.

But weekend data reported by British Columbia on Monday also raised the daily totals for Saturday and Sunday even further past that threshold. Saturday marked a new daily record of 6,488 infections, while Sunday brought another 6,195.

Read more:
Canada hints at ‘major’ coronavirus recovery plan but still no brakes on spending

Those cases now bring the national total to 377,806 cases since the beginning of the pandemic. Of those, 299,972 are considered to be recovered, while another 2,545 patients are currently in hospital.

Story continues below advertisement

Canada’s death toll also rose to 12,130 after 66 new deaths were reported Monday. Another 32 deaths over the weekend in B.C. further added to the total.

November has been a particularly sobering month for the pandemic, as cases and deaths continued to climb despite new restrictions and other efforts from public health officials.

Roughly 140,000 people tested positive over the past 30 days — almost twice the number of new cases in October. It took from the start of the pandemic until mid-September for the country to confirm its first 140,000 cases.

Almost 2,000 people also died of complications from COVID-19 in November. While not as deadly as the first spring peak when roughly 150 people were dying daily, deaths have been steadily climbing along with infections.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

The federal government closed the month by providing an update on the country’s economy, which pegged the current deficit projections at $382 billion this fiscal year and confirmed the government plans to issue a formal budget next year.

Story continues below advertisement

Deputy Prime Minister and Finance Minister Chrystia Freeland said Canada’s economic recovery will likely not begin until “deep into 2021,” but few details on how that recovery will be achieved were revealed Monday.

Freeland told the House of Commons the federal deficit likely won’t return to pre-pandemic levels until at least 2026, due to expected extensive spending on social programs and continued economic restrictions to curb the spread of the virus.


Click to play video 'Ottawa releases much-anticipated fall economic statement'



3:38
Ottawa releases much-anticipated fall economic statement


Ottawa releases much-anticipated fall economic statement

In the meantime, health officials are urging everyone to do their part and follow those restrictions into next year, as Canada and the rest of the world anxiously awaits the arrival of a vaccine.

“As with our last effort to bend the curve, and more so now, this is not going to be a quick solution but a test of our determination and endurance,” Canada’s chief medical health officer Dr. Theresa Tam said in a statement.

Story continues below advertisement

“While now is not the time to gather, we can take comfort in knowing that the sacrifices we are making today are for our tomorrow.

Read more:
What the fiscal update does and doesn’t tell us about the coronavirus vaccine roll-out

Ontario and Quebec, which have each been reporting over 1,000 daily cases for weeks, announced 1,746 and 1,333 new infections Monday, respectively. Quebec also reported another 23 new deaths, while officials announced eight more people have died in Ontario since Sunday.

Saskatchewan and Manitoba each reported over 300 new cases. Thirteen more deaths were also announced in the two Prairie provinces, with two in Saskatchewan and 11 in Manitoba.

Alberta nearly matched Ontario’s daily case total with 1,733 new infections, setting a new daily record, along with eight additional deaths. The province continues to lead the country in active cases, with officials warning hospitals are being pushed to their limits.


Click to play video 'Stress, defiance rise along with COVID-19 cases, restrictions'



2:46
Stress, defiance rise along with COVID-19 cases, restrictions


Stress, defiance rise along with COVID-19 cases, restrictions

In B.C., 596 new cases and 14 more deaths were reported Monday, while officials also revealed over 700 new cases were added both Saturday and Sunday. Another 277 historical cases from earlier in November were also added.

Story continues below advertisement

In Atlantic Canada, six new cases were reported in New Brunswick while Nova Scotia announced 16 more people had tested positive.

One new case was also reported in Newfoundland and Labrador, which on Monday further tightened its border to travellers after leaving the Atlantic travel bubble last week. Starting Tuesday, all essential travellers will have to submit a form and obtain a reference number to show border officials when they arrive.

Read more:
Fiscal update would boost child benefit and wage subsidy, calls for airline refunds

Two of the three territories also saw new cases Monday, with Yukon adding one and Nunavut reporting four.

Nunavut is planning to lift its two-week lockdown on Wednesday, as the number of active cases has finally started to trend downward after an explosion in cases this month.

The pandemic has now infected over 63.1 million people around the world and killed more than 1.46 million, according to data compiled by Johns Hopkins University.

— With files from Global’s Amanda Connolly

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)



Source link

Continue Reading

News

AMC expects people to return to theaters as vaccine rollout gathers pace

Published

 on

(Reuters) -AMC Entertainment Holdings said on Thursday its business was expected to improve in the coming months as the mass rollout of COVID-19 vaccines draws moviegoers back to the cinema chain’s theaters.

A strong slate of big-budget movies, including “Fast & Furious” film “F9” and Marvel’s “Black Widow,” in the summer is expected to fuel a rebound in box-office sales after the pandemic-driven slump in 2020.

“We finally can now say that we are looking at an increasingly favorable environment for movie-going and for AMC as a company over the coming few months, Chief Executive Officer Adam Aron said in a statement.

However, the company’s revenue fell to $148.3 million in the quarter ended March 31, from $941.5 million a year earlier, missing a Refinitiv IBES estimate of $153.43 million.

Its net loss shrunk to $567.2 million, or $1.42 per share in the quarter, from a loss of $2.18 billion, or $20.88 per share, a year earlier.

(Reporting by Chavi Mehta in Bengaluru; Editing by Aditya Soni)

Continue Reading

News

Drugmakers say Biden misguided over vaccine patent waiver

Published

 on

By Stephanie Nebehay and Ludwig Burger

GENEVA/FRANKFURT (Reuters) -Drugmakers on Thursday said U.S. President Joe Biden’s support for waiving patents of COVID-19 vaccines could disrupt a fragile supply chain and that rich countries should instead share more generously with the developing world.

Biden on Wednesday threw his support behind waiving intellectual property rights for COVID-19 vaccines, angering research-based pharmaceutical companies.

If adopted by the World Trade Organisation, the proposal would invite new manufacturers that lack essential know-how and oversight from the inventors to crowd out established contractors, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said.

“I have heard many (vaccine makers) talking about ‘our resources are stretched, our technicians are stretched’,” IFPMA Director General Thomas Cueni told Reuters. He warned of a possible free for all if “sort of rogue companies” were allowed to become involved.

Vaccine developers echoed his comments that waiving intellectual property rights was not a solution.

“Patents are not the limiting factor for the production or supply of our vaccine. They would not increase the global production and supply of vaccine doses in the short and middle term,” said Germany’s BioNTech, which aims to supply up 3 billion doses together with Pfizer this year.

BioNTech said it took more than a decade to develop its vaccines manufacturing process and replicating it required experienced personnel and a meticulous technology transfer, among several other factors beyond patents.

Another German company CureVac, which hopes to release trial results on its messenger ribonucleic acid (mRNA) vaccine as early as this month, said patents were not to blame for supply bottlenecks.

“Since mRNA technology has emerged as the key technology in the fight against COVID-19, the world now needs the same raw materials in unfathomable amounts. The biggest problem is how to coordinate this,” a spokeswoman said.

IFPMA’s Cueni said the real bottlenecks were trade barriers, in particular the U.S. Defense Production Act (DPA).

The DPA is a decades-old U.S. law that prioritised procurement orders related to U.S. national defence, but it has been widely used in non-military crises, such as natural disasters.

Cueni said the way to kickstart low-income countries’ vaccination campaigns was for rich countries to donate vaccine, rather than widen eligibility to young and healthy people at home.

Moderna, which on Thursday reported quarterly results, said waiving intellectual property rights would not help to increase supply of its vaccines in 2021 and 2022.

The U.S. drugmaker said last year it would not enforce its vaccine patents. CureVac said on Thursday it would also not enforce its patents during the pandemic and that it knew of no other developer that would.

Italy’s ReiThera which is in late-stage tests on an experimental COVID-19 vaccine, was also critical of patent waivers.

“There is proprietary know-how that has to be transferred by the owner. And then there is the problem with process materials, which at the moment have delivery times of almost a year,” ReiThera’s chief of technology Stefano Colloca said.

In contrast to the industry reaction, the GAVI vaccine alliance, which co-leads the COVAX dose-sharing programme with the WHO and faces major supply constraints, welcomed Biden’s support for waiving intellectual property rights.

(Writing by Ludwig BurgerAdditional Reporting by Emilio Parodi in Milan; editing by Barbara Lewis and Jane Merriman)

Continue Reading

News

EU supports COVID vaccine patent waiver talks, but critics say won’t solve scarcity

Published

 on

By Philip Blenkinsop and Carl O’Donnell

BRUSSELS/NEW YORK (Reuters) -The European Union on Thursday backed a U.S. proposal to discuss waiving patent protections for COVID-19 vaccines, but drugmakers and some other governments opposed the idea, saying it would not solve global inoculation shortages.

European Commission President Ursula von der Leyen expressed willingness to explore a waiver after President Joe Biden on Wednesday promoted the plan, reversing the U.S. position.

“The main thing is, we have to speed this up,” U.S. Secretary of State Anthony Blinken said on Thursday as India battled a devastating COVID-19 outbreak. “None of us are going to be fully safe until … we get as many people vaccinated as possible.”

A patent waiver is “one possible means of increasing manufacture, and access to vaccines,” he said, as the White House denied a split among officials over the waiver idea.

Biden’s administration endorsed negotiations at the World Trade Organization to gain global agreement.

WTO Director-General Ngozi Okonjo-Iweala told member states that she “warmly welcomed” the U.S. move. “We need to respond urgently to COVID-19 because the world is watching and people are dying,” she said.

World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus reached for capital letters in a tweet calling Biden’s move a “MONUMENTAL MOMENT IN THE FIGHT AGAINST #COVID19,” and said it reflected “the wisdom and moral leadership of the United States.”

Despite that enthusiasm, drugmakers, who stand to lose revenue if they are stripped of patent rights to COVID-19 vaccines, and other critics found flaws in the proposal.

The complexities of manufacturing means free access to the intellectual property is not enough to immediately increase vaccine production, they said. Moderna waived its patent rights in October, and on Thursday noted the lack of companies able to rapidly manufacture a similar vaccine and secure approval for it.

Combined, Pfizer Inc and Moderna Inc have forecast over $45 billion in sales this year for their COVID-19 vaccines.

In the long term, a waiver would discourage pharmaceutical companies from rapidly responding to future global health threats with large research investments, some said.

Germany, the EU’s biggest economic power and home to a large pharmaceutical sector, rejected the idea, saying vaccine shortages were due to limited production capacity and quality standards rather than patent protection issues.

Health Minister Jens Spahn said he shared Biden’s goal of providing the whole world with vaccines. But a government spokeswoman said in a statement that “the protection of intellectual property is a source of innovation and must remain so in the future.”

Moreover, a waiver would take months to negotiate and require unanimous agreement among the 164 countries in the WTO. Drug companies urged rich countries instead to share vaccines more generously with the developing world.

DOES NOT ADDRESS ‘THE REAL CHALLENGES’

Stock prices for drugmakers largely recovered after initially falling sharply after Biden backed the waiver idea. Moderna was off 1.3% after earlier dropping 12%, and the U.S. shares of its German partner BioNTech SE shed 0.6% after falling as much as 15% earlier. “The bottleneck is neither access nor patents (or price) butsimply that there aren’t enough vials, raw materials, etc tomanufacture it regardless of patents,” Jefferies analyst Michael Yee said of expanding COVID-19 vaccine production.

The pharmaceutical industry’s main lobbying group, PhRMA, said: “This decision does nothing to address the real challenges to getting more shots in arms, including last-mile distribution and limited availability of raw materials.”

There have been more than 155 million confirmed coronavirus infections worldwide and almost 3.4 million peopled have died for COVID-19, according to a Reuters tally.

But the vast bulk of the 624 million people who have received at least one dose of the vaccine, according to the Our World in Data website, live in wealthier countries.

The global COVAX vaccine distribution program, led by the WHO and the Global Alliance for Vaccines and Immunization (GAVI), that aims to supply vaccines to low-income countries, has so far handed out around 41 million doses.

French President Emmanuel Macron said he was “very much in favour” of opening up intellectual property. However, a French government official said vaccine shortages was the result of a lack of production capacity and ingredients, not of patents.

“I would remind you that it is the United States that has not exported a single dose to other countries, and is now talking about lifting the patents,” the official said.

The United States has shipped a few million vaccine doses it was not using to Mexico and Canada on loan.

South Africa and India made the initial waiver proposal at the WTO in October, gathering support from many developing countries, which say it will make vaccines more widely available.

Until now, the European Union has been aligned with a group of countries, including Britain and Switzerland – home to large pharmaceutical companies – that have opposed the waiver.

(Reporting by Philip Blenkinsop and Sabine Siebold in Brussels, additional reporting by Robin Emmott, Francesco Guarascio and John Chalmers in Brussels, Emilio Parodi in Milan, Gwenaelle Barzic in Paris, Emma Farge in Geneva; Additional reporting by Trevor Hunnicutt aboard Air Force One, Andrea Shalal in Washington, Carl O’Donnell and Michelle Nichols in New York, and Ankur Banerjee in Bengaluru; Writing by Nick Macfie and Cynthia Osterman; Editing by Kevin Liffey, Mark Heinrich and Bill Berkrot)

Continue Reading

Trending